20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Update

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 128,775 shares, an increase of 613.4% from the May 14th total of 18,050 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 1,125,074 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AIDX. Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th. Maxim Group began coverage on 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 price objective for the company. Finally, Weiss Ratings assumed coverage on 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Trading Down 6.0%

Shares of NASDAQ AIDX opened at $0.79 on Wednesday. 20/20 Biolabs has a 12-month low of $0.78 and a 12-month high of $50.00. The firm has a 50-day simple moving average of $1.44.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.28) earnings per share (EPS) for the quarter. The business had revenue of $0.35 million for the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.